Skip to main
AKTX

Akari Therapeutics (AKTX) Stock Forecast & Price Target

Akari Therapeutics (AKTX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Akari Therapeutics PLC is developing AKTX-101, a preclinical stage Trop2-targeting antibody-drug conjugate (ADC) that has shown promising preclinical efficacy against bladder and gastric cancers, particularly in combination with immuno-oncology agents. The preclinical data suggests that AKTX-101 not only demonstrates significant anti-tumor activity but also potentially generates immunological memory, enhancing long-term protection against tumor rechallenge. The novel ADC platform may lead to best-in-class therapeutic outcomes, especially when integrated with existing immunotherapies, which positions Akari favorably within the oncology landscape.

Bears say

Akari Therapeutics PLC presents a promising ADC platform; however, its weak balance sheet poses a significant risk that could negatively impact investor sentiment. The potential financial overhang is expected to weigh on the stock, particularly as the company seeks to secure additional funding for its ongoing and planned preclinical and clinical programs. Until such funding is obtained, continued concerns regarding financial stability may hinder the company's stock performance.

Akari Therapeutics (AKTX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Akari Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Akari Therapeutics (AKTX) Forecast

Analysts have given Akari Therapeutics (AKTX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Akari Therapeutics (AKTX) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Akari Therapeutics (AKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.